Amantadine HCl Tablets Rx
Generic Name and Formulations:
Amantadine HCl 100mg; tabs.
Various generic manufacturers
Indications for Amantadine HCl Tablets:
Parkinsonism. Drug-induced extrapyramidal reactions.
Parkinsonism monotherapy: initially 100mg twice daily, may increase after 1–2 weeks by 100mg daily. Serious associated illness or high doses of other antiparkinson drugs: 100mg once daily, may increase after 1 to several weeks to 100mg twice daily; max 400mg/day in divided doses. Extrapyramidal disorders: 100mg twice daily; max 300mg/day in divided doses. Renal dysfunction: reduce dose; see literature.
Adjust dose gradually. History of seizures. Heart failure. Orthostatic hypotension. Peripheral edema. Renal (CrCl <50mL/min) or hepatic dysfunction. Psychiatric disorders. Suicidal ideation. History of recurrent eczematoid rash. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with CNS stimulants. Thioridazine may worsen tremor in elderly patients with parkinsonism.
Neuroleptic malignant syndrome (when drug is withdrawn or dose is reduced), nausea, dizziness, insomnia, heart failure, anxiety, irritability, hallucinations, confusion, anorexia, anticholinergic effects, constipation, ataxia, livedo reticularis, peripheral edema, orthostatic hypotension, headache, somnolence, dream abnormality, diarrhea, fatigue.
Formerly known under the brand name Symmetrel.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally